Andrew A. Wolff

Sort by:

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.

Bernard R. Chaitman, Sandra L. Skettino, +8 authors Andrew A. Wolff
Journal of the American College of Cardiology
2004

OBJECTIVES The primary objective of the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial was to determine the dose-response relationship of ranolazine, a potentially new… (More)

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

John Gf Cleland, John R. Teerlink, +18 authors Fady I. Malik
The Lancet
2011

BACKGROUND Many patients with heart failure remain symptomatic and have a poor prognosis despite existing treatments. Decreases in myocardial contractility and shortening of ventricular systole are… (More)

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

John R. Teerlink, Cyril P Clarke, +10 authors Andrew A. Wolff
The Lancet
2011

BACKGROUND Decreased systolic function is central to the pathogenesis of heart failure in millions of patients worldwide, but mechanism-related adverse effects restrict existing inotropic treatments.… (More)

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.

David A. Morrow, Benjamin M. Scirica, +7 authors Eugene Braunwald
JAMA
2007

CONTEXT Ranolazine is a novel antianginal agent that reduces ischemia in patients with chronic angina but has not been studied in patients with acute coronary syndromes (ACS). OBJECTIVE To… (More)

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

Bernard R. Chaitman, Carl J Pepine, +6 authors Andrew A. Wolff
JAMA
2004

CONTEXT Many patients with chronic angina experience anginal episodes despite revascularization and antianginal medications. In a previous trial, antianginal monotherapy with ranolazine, a drug… (More)

Ranolazine Stimulates Glucose Oxidation in Normoxic, Ischemic, and Reperfused Ischemic Rat Hearts

James G. McCormack, Rick L. Barr, Andrew A. Wolff, Gary D Lopaschuk
Circulation
1996

BACKGROUND Ranolazine is a novel antianginal agent that may reduce symptoms without affecting hemodynamics and has shown cardiac antiischemic effects in in vivo and in vitro models. In one study it… (More)

Histamine and cardiac arrhythmias.

Andrew A. Wolff, Rafael Levi
Circulation research
1986

Modification of the cardiac rhythm by histamine has been appreciated almost since the compound's isolation from ergot by Barger and Dale in 1910. The major arrhythmogenic actions of histamine are an… (More)

Ranolazine: a novel metabolic modulator for the treatment of angina.

James G. McCormack, William Stanley, Andrew A. Wolff
General pharmacology
1998

1. Ranolazine shifts ATP production away from fatty acid oxidation toward glucose oxidation. 2. Because more oxygen is required to phosphorylate a given amount of ATP during fatty acid oxidation than… (More)

A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.

Carl J Pepine, Andrew A. Wolff
The American journal of cardiology
1999

We assessed efficacy and safety of a new anti-ischemic agent, ranolazine, during a randomized, double-blind, placebo-controlled crossover study. In the qualifying phase, we withdrew at least 1… (More)

Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure.

Margaret P. Chandler, William Stanley, +5 authors Hani N. Sabbah
Circulation research
2002

The present study assesses whether ranolazine increases left ventricular (LV) function without an increase in myocardial oxygen consumption (MVO2) and thus improves LV mechanical efficiency in dogs… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences